Andreessen Horowitz investment partner Jay Rughani discusses the paper he and his colleagues published recently about clinical use cases of AI, and outlined steps regulators should take for reimbursing providers using the technology.
Note: Andreessen Horowitz says views expressed by its employees are their own and should not be taken as investment advice. More details at https://a16z.com/disclosures/
